Assenagon Asset Management S.A. Trims Stock Position in DaVita Inc. (NYSE:DVA)

Assenagon Asset Management S.A. cut its position in DaVita Inc. (NYSE:DVA - Free Report) by 81.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,530 shares of the company's stock after selling 61,087 shares during the quarter. Assenagon Asset Management S.A.'s holdings in DaVita were worth $2,070,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. United Capital Financial Advisors LLC grew its position in DaVita by 2.6% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after acquiring an additional 62 shares in the last quarter. Freedom Investment Management Inc. grew its holdings in shares of DaVita by 3.6% in the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after purchasing an additional 62 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of DaVita by 2.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares in the last quarter. UMB Bank n.a. increased its stake in DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the period. Finally, Coppell Advisory Solutions LLC lifted its holdings in DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research note on Friday, February 21st. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Finally, Truist Financial cut their price target on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, DaVita has a consensus rating of "Hold" and an average price target of $164.50.

DaVita Stock Up 0.7%

Shares of DVA stock traded up $0.96 on Friday, reaching $136.75. 406,802 shares of the stock were exchanged, compared to its average volume of 859,862. The company has a market capitalization of $10.32 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.94 and a beta of 1.11. The business's 50 day moving average price is $140.22 and its 200 day moving average price is $150.38. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. DaVita Inc. has a twelve month low of $131.76 and a twelve month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The company had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the previous year, the business earned $2.26 EPS. DaVita's revenue for the quarter was up 5.0% on a year-over-year basis. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.